Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with…more
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with…more
Latest RNS from Oxford Biomedica plc
- holdingsHolding(s) in Company
- holdingsHolding(s) in Company
- holdingsHolding(s) in Company
- holdingsHolding(s) in Company
- trading_updateHalf Year Trading Update and Notice of Results
Analyst consensus: Buy
As of 21 Sept 2026, 8 analysts rate Oxford Biomedica plc a Buy, with 63% buy ratings and a mean price target of 704p (range 508p–900p), +52% vs the current price.